Funded Project Details - FY2021
|Title:|| Novel selective substituted aminofurazans kinase inhibitors for Drug resistant Bacteria|
Robert T Striker
|Congressional District Code:
||Biomedical Laboratory R&D
|| January 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Antibiotic resistant bacteria are a major threat to human health. Each year in the United States, approximately 2 million people are infected with bacteria that are resistant to antibiotics resulting in at least 23,000 deaths. The development of novel antibiotics is needed. However, de novo antibiotic development is resource intensive. Given the poor return on investment, major pharmaceutical companies have significantly decreased antibiotic Research and Development efforts. Academic labs genera...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.